ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

WSJ BLOG/Health: A.M. Vitals: Health-Care Overhaul Case Ripples Outward

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Mark Long Here's what's making health news this morning: Health Case Ripples Outward (WSJ): After three days of arguments over the constitutionality of the health-care overhaul, it's impossible to predict how the Supreme Court will rule, but skepticism from some justices heightens the possibility it could be overturned in June. Also: Three Days of Hearings Yield Five Take-Aways. Obesity-Linked Cancers Increase (WSJ): Overall cancer diagnoses in the U.S. have dropped, but several cancers linked to obesity and a sedentary lifestyle have risen each year from 1999 through 2008. Cancer: 'Book of Knowledge' Published (BBC): A large "encyclopedia" detailing how hundreds of different cancer cell lines interact with drugs that could speed development of new treatments was published in Nature. In Cancer Science, Many "Discoveries" Don't Hold Up (Reuters): Forty-seven of 53 "landmark" cancer studies from reputable labs couldn't be replicated, the former head of cancer research for Amgen said in a commentary piece in Nature, dimming the prospects for new drug development. FDA Asks Chelsea Therapeutics for More Data on Northera (Dow Jones Newswires): The FDA declined to approve Northera, a low-blood-pressure drug from Chelsea Therapeutics, saying additional data showing efficacy was required. Image source: iStockphoto -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/11/201619:01:00New Drug Treatment Kyprolis® ▼ (carfilzomib) for Relapsed Mu...
02/10/201613:38:31Amended Statement of Ownership (sc 13g/a)
02/10/201610:17:35Amended Statement of Ownership (sc 13g/a)
02/09/201618:20:00Panel Recommends FDA Approval of Remicade Knockoff
02/09/201618:16:00Panel Recommends FDA Approval of Remicade Knockoff
02/07/201618:15:00Drug Industry Launches Ad Campaign Aimed at Lawmakers
02/05/201617:06:00Amgen To Present At The Leerink Partners 5th Annual Global Healthcare...
02/04/201616:17:00Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint...
02/04/201616:00:00Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3...
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:31:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:00:00Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And...
01/25/201617:20:00FDA Accepts Amgen's Biosimilar Biologics License Application...
01/25/201616:03:00Amgen Announces Webcast of 2015 Fourth Quarter and Full Year...
01/23/201613:00:00Vectibix® (panitumumab) And Best Supportive Care Improves Overall...
01/22/201601:00:00Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor...
01/21/201616:32:00FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy...
01/11/201612:50:00Celgene Names New CEO, Cuts 2015 Profit Outlook
01/10/201620:33:00Drugmakers Keep Raising Prices Despite Criticisms
01/07/201616:05:00Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad